Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status

Breast

Volumn 20, Issue 1, 2011, Pages 78-85

  Kim, Hee Jeong ^a   Kim, Mi Jung ^a   Ahn, Sei Hyun ^a   Son, Byung Ho ^a   Kim, Sung Bae ^a   Ahn, Jin Hee ^a   Noh, Woo Chul ^b   Gong, Gyungyub ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

Breast cancer; CD24; CD44; Hormone receptor status

Indexed keywords

CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

EID: 79451473946     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.08.001     Document Type: Article

References (32)

1. Ahn S.H. Personal experience of 1,000 breast cancer surgeries in Korea. J Korean Cancer Assoc 2000, 32:68-75.
2. Son B.H., Kwak H.S., Lee P.C., Ko B.K., Kim J.S., Ahn S.H. Clinical analysis of breast cancer surgeries in Korea. J Korean Surg Soc 2001, 60:470-476.
3. Society Tkbc Survival analysis of Korean breast cancer patients diagnosed between 1993 and 2002 in Korea-a nationwide study of the cancer registry. J Breast Cancer 2006, 9:214-218.
4. Kakarala M., Wicha M.S. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008, 26:2813-2820.
5. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
6. + tumor cells in invasive breast carcinomas. Hum Pathol 2008, 39:1096-1102.
7. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005, 11:1154-1159.
8. Dontu G., El-Ashry D., Wicha M.S. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004, 15:193-197.
9. Chang C.C. Recent translational research: stem cells as the roots of breast cancer. Breast Cancer Res 2006, 8:103.
10. Robbins P., Pinder S., de Klerk N., Dawkins H., Harvey J., Sterrett G., et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995, 26:873-879.
11. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41:154-161.
12. Campbell L.L., Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 2007, 6:2332-2338.
13. Kristiansen G., Denkert C., Schluns K., Dahl E., Pilarsky C., Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002, 161:1215-1221.
14. Kristiansen G., Pilarsky C., Pervan J., Sturzebecher B., Stephan C., Jung K., et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004, 58:183-192.
15. Kristiansen G., Pilarsky C., Wissmann C., Kaiser S., Bruemmendorf T., Roepcke S., et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005, 205:359-376.
16. Kristiansen G., Schluns K., Yongwei Y., Denkert C., Dietel M., Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 2003, 88:231-236.
17. Kristiansen G., Winzer K.J., Mayordomo E., Bellach J., Schluns K., Denkert C., et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003, 9:4906-4913.
18. Fogel M., Friederichs J., Zeller Y., Husar M., Smirnov A., Roitman L., et al. CD24 is a marker for human breast carcinoma. Cancer Lett 1999, 143:87-94.
19. Kim H.J., Kim J.B., Lee K.-M., Shin I., Han W., Ko E., et al. Isolation of CD24high and CD24low/- cells from MCF-7: CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7. Cancer Lett 2007, 258:98-108.
20. Schabath H., Runz S., Joumaa S., Altevogt P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 2006, 119:314-325.
21. Dupont V.N., Gentien D., Oberkampf M., De Rycke Y., Blin N. A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. Int J Cancer 2007, 121:1036-1046.
22. Nestl A., Von Stein O.D., Zatloukal K., Thies W.G., Herrlich P., Hofmann M., et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 2001, 61:1569-1577.
23. Surowiak P., Materna V., Paluchowski P., Matkowski R., Wojnar A., Maciejczyk A., et al. CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. Anticancer Res 2006, 26:629-634.
24. Surowiak P., Materna V., Gyorffy B., Matkowski R., Wojnar A., Maciejczyk A., et al. Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer 2006, 95:339-346.
25. Bircan S., Kapucuoglu N., Baspinar S., Inan G., Candir O. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol - Res Pract 2006, 202:569-576.
26. Tempfer C., Losch A., Heinzl H., Hausler G., Hanzal E., Kolbl H., et al. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur J Cancer 1996, 32A:2023-2025.
27. Sinn H.P., Heider K.H., Skroch-Angel P., von Minckwitz G., Kaufmann M., Herrlich P., et al. Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res Treat 1995, 36:307-313.
28. Kaufmann M., Heider K.H., Sinn H.P., von Minckwitz G., Ponta H., Herrlich P. CD44 isoforms in prognosis of breast cancer. Lancet 1995, 346:502.
29. Dall P., Heider K.H., Sinn H.P., Skroch-Angel P., Adolf G., Kaufmann M., et al. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995, 60:471-477.
30. Sleeman J.P., Cremers N. New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment. Clin Exp Metastasis 2007, 24:707-715.
31. +/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008, 10:R53.
32. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.